Artivion (NYSE:AORT) SVP Andrew Green Sells 44,001 Shares of Stock

Artivion, Inc. (NYSE:AORT) SVP Andrew Green sold 44,001 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the sale, the senior vice president owned 60,259 shares in the company, valued at $1,247,361.30. The trade was a 42.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Artivion Stock Performance

Artivion stock opened at $20.98 on Tuesday. The company has a quick ratio of 2.80, a current ratio of 3.86 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $1.02 billion, a P/E ratio of 87.42 and a beta of 1.27. The stock’s 50 day moving average is $28.66 and its 200 day moving average is $36.79. Artivion, Inc. has a twelve month low of $19.16 and a twelve month high of $48.25.

Hedge Funds Weigh In On Artivion

Several hedge funds and other institutional investors have recently modified their holdings of AORT. Caitong International Asset Management Co. Ltd bought a new position in Artivion in the 3rd quarter worth $27,000. Aster Capital Management DIFC Ltd raised its holdings in Artivion by 402.3% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after purchasing an additional 519 shares during the period. Rockefeller Capital Management L.P. raised its holdings in Artivion by 150.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after purchasing an additional 399 shares during the period. Larson Financial Group LLC raised its holdings in Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after purchasing an additional 563 shares during the period. Finally, USA Financial Formulas raised its holdings in Artivion by 163.5% in the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after purchasing an additional 703 shares during the period. 86.37% of the stock is owned by institutional investors.

Analysts Set New Price Targets

AORT has been the topic of several recent research reports. Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. LADENBURG THALM/SH SH upgraded Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price target on the stock in a research note on Friday, April 10th. Needham & Company LLC cut their target price on Artivion from $58.00 to $44.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Stifel Nicolaus set a $45.00 target price on Artivion in a research note on Monday, June 1st. Finally, Citizens Jmp cut their target price on Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research note on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Artivion has an average rating of “Moderate Buy” and an average target price of $46.17.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.